natgillin/translations-raw huggingface dataset:
The following side effects were seen more frequently in children and adolescents in the clinical study: Fatigue (very common), painful bowel movements (very common), and feeling dizzy or lightheaded (common).
Naslednje neželene učinke so v klinični študiji ugotavljali pogosteje pri otrocih in mladostnikih: utrujenost (zelo pogosta), bolečine pri iztrebljanju blata (zelo pogoste) in občutek omotice ali vrtoglavosti (pogost).
The following side effects were very rarely observed during clinical studies (less than 1 case in 10 000 administrations given to patients): fever (pyrexia), increased C-reactive protein, wheals (urticaria), itching (pruritus), rash and dizziness.
Naslednje neželene učinke so zelo redko opažali med kliničnimi študijami (manj kot 1 primer na 10.000 dajanj zdravila bolnikom): zvišana telesna temperatura (pireksija), zvišana vrednost C reaktivnega proteina, koprivnica (urtikarija), srbenje (pruritus), izpuščaj in omotica.
The following side effects with imiquimod were reported:
V zvezi z uporabo imikvimoda so poročali o naslednjih neželenih učinkih:
The following statements refer to AVAGLIM or the two individual active substances (rosiglitazone and glimepiride).
Naslednje navedbe veljajo za AVAGLIM ali posamezni zdravilni učinkovini (rosiglitazon in glimepirid).
The following statements reflect the pharmacokinetic properties of the individual active substances of Competact.
Sledeče ugotovitve odražajo farmakokinetične lastnosti individualnih zdravilnih učinkovin v zdravilu Competact.
The following statements reflect the pharmacokinetic properties of the individual active substances of Efficib.
V nadaljevanju so naštete farmakokinetične lastnosti posameznih zdravilnih učinkovin v zdravilu Efficib.
The following statements reflect the pharmacokinetic properties of the individual active substances of Eucreas.
Naslednje trditve opisujejo farmakokinetične lastnosti posameznih učinkovin zdravila Eucreas.
The following statements reflect the pharmacokinetic properties of the individual active substances of Janumet.
V nadaljevanju so naštete farmakokinetične lastnosti posameznih zdravilnih učinkovin v zdravilu Janumet.
The following statements reflect the pharmacokinetic properties of the individual active substances of Jentadueto
Trditve v nadaljevanju temeljijo na farmakokinetičnih lastnostih posamičnih zdravilnih učinkovin v zdravilu Jentadueto.
The following statements reflect the pharmacokinetic properties of the individual active substances of Ristfor.
V nadaljevanju so naštete farmakokinetične lastnosti posameznih zdravilnih učinkovin v zdravilu Ristfor.
The following statements reflect the pharmacokinetic properties of the individual active substances of Velmetia.
V nadaljevanju so naštete farmakokinetične lastnosti posameznih zdravilnih učinkovin v zdravilu Velmetia.
The following statements reflect the pharmacokinetic properties of the individual components of AVAGLIM.
Naslednje navedbe temeljijo na farmakokinetičnih lastnostih posameznih sestavin AVAGLIMA.
The following statements reflect the preclinical safety results of the individual active substances of EVOTAZ.
V nadaljevanju navajamo predklinične podatke o varnosti, pridobljene s posameznima zdravilnima učinkovinama zdravila EVOTAZ.
The following step-by-step instruction is intended for self-administration only.
Naslednja navodila po korakih so namenjena samo samoinjiciranju.
The following strong P-gp inhibitors are contraindicated: systemic ketoconazole, cyclosporine, itraconazole and dronedarone (see section 4.3).
Naslednji močni zaviralci P-gp so kontraindicirani: sistemski ketokonazol, ciklosporin, itrakonazol in dronedaron (glejte poglavje 4.3).
The following study endpoints demonstrated a statistically significant advantage in favour of ZYTIGA treatment:
Naslednji cilji opazovanja so pokazali statistično značilno prednost v prid uporabe zdravila ZYTIGA:
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide: Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox, clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs, octreotide, alcohol, and anabolic steroids.
Naslednje učinkovine lahko povečajo in/ali podaljšajo hipoglikemični učinek repaglinida: gemfibrozil, klaritromicin, itrakonazol, ketokonazol, trimetoprim, ciklosporin, deferasiroks, klopidogrel, drugi antidiabetiki, zaviralci monoaminooksidaze (MAOI), neselektivni zaviralci beta, zaviralci angiotenzinske konvertaze (ACE), salicilati, NSAID, oktreotid, alkohol in anabolni steroidi.
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide: Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox, clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs, octreotide, alcohol, and anabolic steroids.
Naslednje učinkovine lahko povečajo in/ali podaljšajo hipoglikemični učinek repaglinida: gemfibrozil, klaritromicin, itrakonazol, ketokonazol, trimetoprim, ciklosporin, deferasiroks, klopidogrel, drugi antidiabetiki, zaviralci monoaminooksidaze (zaviralci MAO), neselektivni antagonisti adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (zaviralci ACE), salicilati, nesteroidna protivnetna zdravila, oktreotid, alkohol in anabolni steroidi.
The following substances may increase the patient’s insulin requirement:
Bolnikovo potrebo po insulinu lahko zvečajo naslednje snovi:
The following substances may increase the patient’s insulin requirement:
Naslednja zdravila lahko povečajo potrebo bolnika po insulinu:
The following substances may increase the patient’s insulin requirements:
Bolnikovo potrebo po insulinu lahko zvečajo naslednje snovi:
The following suggestions are based on pharmacological considerations and have not been evaluated in clinical trials.
Naslednji predlogi so osnovani glede na farmakologijo in niso bili vrednoteni v kliničnih preskušanjih.
The following symptoms may occur in new-born babies, of mothers that have received Abilify Maintena in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih, katerih matere so v zadnjih treh mesecih nosečnosti prejemale zdravilo Abilify Maintena, se lahko pojavijo naslednji simptomi: tresenje, okorelost in/ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies of mothers that have used Olanzapine Mylan in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih, katerih matere so v zadnjem trimestru (zadnjem trimeseju nosečnosti) jemale zdravilo OLANZAPIN MYLAN, se lahko pojavijo naslednji simptimi; tresenje, mišična okorelost, in/ali šibkost, zaspanost, razdražljivost, težave z dihanjem in hranjenjem.
The following symptoms may occur in newborn babies, of mothers that have used ABILIFY oral solution in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale peroralno raztopino ABILIFY, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used ABILIFY orodispersible tablets in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo ABILIFY orodisperzibilne tablete, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used ABILIFY solution for injection in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale raztopino za injiciranje ABILIFY, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used ABILIFY tablets in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo ABILIFY tablete, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used Aripiprazole Mylan Pharma tablets in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Aripiprazol Mylan Pharma tablete, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used Aripiprazole Sandoz tablets in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Aripiprazol Sandoz tablete, se lahko pojavijo naslednji simptomi: tresenje, okornost in/ali šibkost mišic, zaspanost, vznemirjenost, težave z dihanjem in motnje pri hranjenju.
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Glenmark in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Olanzapin Glenmark, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Teva in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Olanzapin Teva, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used Olazax Disperzi in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo Olazax Disperzi, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used OLAZAX in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo OLAZAX, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used ZYPAHDERA in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo ZYPADHERA, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following symptoms may occur in newborn babies, of mothers that have used ZYPREXA VELOTAB in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Pri novorojenčkih mater, ki so v zadnjih treh mesecih nosečnosti uporabljale zdravilo ZYPREXA VELOTAB, se lahko pojavijo naslednji simptomi: tresenje, okornost ali šibkost mišic, zaspanost, nemir, težave z dihanjem in motnje hranjenja.
The following table (table 1) shows all treatment-emergent adverse reactions from placebo-controlled studies in patients treated for weight loss and related metabolic disorders when these incidences were statistically significantly greater than the corresponding placebo rate (for events  1%) or considered clinically relevant (for events < 1%).
Naslednja tabela (tabela 1) prikazuje vse neželene učinke, ki so se pojavili med zdravljenjem v s placebom kontroliranih študijah, pri bolnikih zdravljenih za zmanjšanje telesne mase in zaradi sorodnih presnovnih motenj, če je bila njihova incidenca statistično značilno večja kot pri placebu (za dogodke 1%) ali so bile ocenjene kot klinično pomembne (za dogodke <1%).
The following table (table 1) shows all treatment-emergent adverse reactions from placebo-controlled studies in patients treated for weight loss and related metabolic disorders when these incidences were statistically significantly greater than the corresponding placebo rate (for events 1%) or considered clinically relevant (for events <1%).
Naslednja tabela (tabela 1) prikazuje vse neželene učinke, ki so se pojavili med zdravljenjem v s placebom kontroliranih študijah, pri bolnikih zdravljenih za zmanjšanje telesne mase in zaradi sorodnih presnovnih motenj, če je bila njihova incidenca statistično značilno večja kot pri placebu (za dogodke 1%) ali so bile ocenjene kot klinično pomembne (za dogodke <1%).
The following table can be used to guide dosing in bleeding episodes and surgery.
Preglednico 1 spodaj lahko uporabljate kot vodilo za odmerjanje pri krvavitvah in kirurških posegih:
The following table can be used to guide dosing in bleeding episodes and surgery:
Naslednjo preglednico lahko uporabite za smernice pri odmerjanju ob krvavitvah in operaciji
The following table contains dosing guidelines for Kaletra tablets based on BSA when used in combination with efavirenz or nevirapine in children.
Naslednja tabela prikazuje smernice za odmerjanje tablet zdravila Kaletra glede na telesno površino, če so tablete pri otrocih uporabljene v kombinaciji z efavirenzem ali nevirapinom.
The following table covers adverse drug reactions from the pooled studies mentioned above in patients with Parkinson’s disease.
V spodnji tabeli so navedeni neželeni učinki zdravila, zbrani v zgoraj omenjenih združenih študijah na bolnikih s Parkinsonovo boleznijo.
The following table covers adverse drug reactions from the pooled studies mentioned above in patients with Parkinson’s disease.
V spodnji tabeli so navedeni neželeni učinki zdravila, zbrani zgoraj omenjenih združenih vseh študijah na bolnikih s Parkinsonovo boleznijo.
The following table covers adverse drug reactions from the pooled studies mentioned above in patients with Restless Legs Syndrome.
V spodnji tabeli so navedeni neželeni učinki zdravila, zbrani v zgoraj omenjenih združenih študijah na bolnikih s sindromom nemirnih nog.
The following table defines the pipette to be used according to the weight of the cat:
Naslednja razpredelnica določa velikost merilne kapalke, ki jo je treba uporabiti glede na težo mačke:
The following table defines the pipette to be used according to the weight of the dog:
Naslednja razpredelnica določa velikost kapalke, ki jo je treba uporabiti glede na težo psa:
The following table defines the pipette to be used according to the weight of the dog:
Naslednja razpredelnica določa velikost merilne kapalke, ki jo je treba uporabiti glede na težo psa:
The following table defines the size of pipette to be used according to the weight of the cat:
Naslednja razpredelnica določa velikost merilne kapalke, ki jo je treba uporabiti glede na težo mačke:
The following table defines the size of pipette to be used according to the weight of the dog:
Naslednja razpredelnica določa velikost merilne kapalke, ki jo je treba uporabiti glede na telesno maso psa:
The following table gives the volume of oral solution in function of patients’ weights.
Naslednja tabela prikazuje volumen peroralne raztopine v odvisnosti od telesne mase bolnika.
The following table has been worked out so that it gives you a calorie target that is about 500 calories fewer per day than your body needs to maintain your current weight.
Naslednja tabela je bila izdelana z namenom, da vam pomaga določiti ciljne vrednosti kalorij na način, da bi vnesli dnevno 500 kalorij dnevno manj, kot jih potrebujete za vzdrževanje svoje telesne mase.
The following table has been worked out so that it gives you a calorie target that is about 500 calories fewer per day than your body needs to maintain your current weight.
Naslednja tabela je bila izdelana z namenom, da vam pomaga določiti ciljne vrednosti kalorij na način, da bi vnesli dnevno 500 kalorij manj kot jih potrebujete za vzdrževanje svoje telesne mase.
The following table includes, the all-causality adverse reactions (MedDRA terms) from 840 subjects receiving 100 mg anidulafungin with frequency corresponding to very common (≥1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and from spontaneous reports with frequency not known (cannot be estimated from the available data).
840 preiskovancih, ki so prejemali 100 mg anidulafungina, s pogostnostjo: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), in iz spontanih poročil s pogostnostjo 'neznana' (ni mogoče oceniti iz razpoložljivih podatkov).
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
V nasledn i tabeli so našteti neželeni učinki in laboratorijske preiskave, ki so jih opazili iz spontanega poročanja in kliničnih preskušanj.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
V naslednj i tabeli so našteti neželeni učinki in laboratorijske preiskave, ki so jih opazili iz spontanega poročanja in kliničnih preskušanj.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
V naslednj ji tabeli so našteti neželeni učinki in laboratorijske preiskave, ki so jih opazili iz spontanega poročanja in kliničnih preskušanj.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
V naslednja tabeli so našteti neželeni učinki in laboratorijske preiskave, ki so jih opazili iz spontanega poročanja in kliničnih preskušanj.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
V naslednji tabeli so - našteti neželeni učinki in laboratorijske preiskave, ki so jih opazili iz spontanega poročanja in kliničnih preskušanj.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
V naslednji tabeli so -našteti neželeni učinki in laboratorijske preiskave, ki so jih opazili iz spontanega poročanja in kliničnih preskušanj.
The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials.
V nNaslednj i tabeli so našteti neželeni učinki in laboratorijske preiskave, ki so jih opazili iz spontanega poročanja in kliničnih preskušanj.
The following table of undesirable effects (first year of treatment) is based on adverse events that occurred at a frequency of > 2 % and with an incidence  1 % above placebo in clinical trials of 1 and 2 years duration:
Spodnja preglednica neželenih učinkov (prvo leto zdravljenja) prikazuje neželene učinke, ki so se pojavili s pogostnostjo > 2 % in z incidenco ≥ 1 % v primerjavi s placebom v kliničnih preskušanjih, ki so potekala 1 ali 2 leti:
The following table of undesirable effects is based on post-marketing spontaneous reports, and therefore the frequency remains unknown:
Spodnja preglednica prikazuje neželene učinke, zbrane preko spontanega sistema poročanja po prihodu zdravila na trg, zato njihova pogostnost ni znana:
The following table presents clinically important adverse reactions of moderate intensity or more occurring among patients receiving maraviroc in Phase 2b/3 studies at rates greater than rates in the comparator.
Naslednja preglednica navaja klinično pomembne neželene učinke, zmerne ali večje jakosti, ki se pojavljajo pri bolnikih, ki so dobivali maravirok v študijah faze 2b/3, z večjo pogostnostjo kot pri primerjalnem zdravilu.
The following table presents how the frequencies are reflected in this section:
Spodnja preglednica prikazuje razvrstitev pogostnosti v tem poglavju:
The following table presents the adverse medicinal product reactions that were reported in placebo- controlled trials in which 1,965 hypertensive patients received irbesartan.
V nadaljevanju so zbrani neželeni učinki zdravila, o katerih so poročali v s placebom kontroliranih preizkušanjih, v katerih je sodelovalo 1965 bolnikov z visokim krvnim tlakom, ki so jemali irbesartan.
The following table provides a guide for factor VIII minimum blood levels.
V naslednji preglednici navodila glede minimalnih ravni faktorja VIII v krvi.
The following table provides the daily dosing recommendations for subjects with renal or hepatic impairment in the absence and presence of moderate and potent CYP3A4 inhibitors (see sections 4.3, 4.4, 4.5 and 5.2).
Spodnja preglednica navaja priporočeno dnevno odmerjanje za bolnike z okvarjenim delovanjem ledvic ali jeter, ob sočasnem prejemanju zmernih in močnih zaviralcev CYP3A4 ali brez njega (glejte poglavja 4.3, 4.4, 4.5 in 5.2).
The following table provides the frequency and severity of ADRs based on results from RAINBOW, a phase 3 study in adult patients with advanced gastric cancer randomised to treatment with ramucirumab in combination with paclitaxel or placebo plus paclitaxel.
V naslednji tabeli pogostnost in resnost neželenih učinkov zdravila temeljita na izidih študije RAINBOW 3. faze pri odraslih bolnikih z napredovalim rakom želodca, ki so bili randomizirani v skupino za zdravljenje z ramucirumabom v kombinaciji s paklitakselom ali pa v skupino za zdravljenje s placebom in paklitakselom.
The following table provides the frequency and severity of the ADRs based on results from RAISE, a phase 3 study in adult patients with mCRC randomised to treatment with ramucirumab plus FOLFIRI or placebo plus FOLFIRI.
V naslednji tabeli sta navedeni pogostnost in resnost neželenih učinkov na podlagi rezultatov iz študije RAISE, študije III. faze pri odraslih bolnikih z metastatskim kolorektalnim rakom, ki so bili randomizirani v skupino za zdravljenje z ramucirumabom in shemo FOLFIRI ali pa v skupino za zdravljenje s placebom in shemo FOLFIRI.